Applications of Boc-3,5-Diiodo-L-Tyrosine in Industrial Manufacturing

Boc-3,5-Diiodo-L-Tyrosine is a specialty intermediate primarily used in active pharmaceutical ingredient (API) production and advanced fine chemical synthesis. Our manufacturing process ensures precise purity and batch consistency, meeting the stringent quality requirements of regulated downstream industries. The following industrial sectors represent the principal areas using this material in scalable manufacturing environments.

1. Peptide Drug Synthesis

This protected diiodo derivative of L-tyrosine serves as a critical high-purity building block for automated solid-phase peptide synthesis. Its introduction into peptide chains enables the incorporation of iodinated tyrosine residues, essential for certain therapeutic analogs and radiolabeled tracers. Customers specify the product for site-specific substitution in peptide sequences designed for thyroid disorder treatments and oncology diagnostics. The N-Boc protection group prevents unwanted side reactions during condensation steps, supporting high-yield, high-fidelity assembly of large peptides. Our material integrates directly into commercial peptide manufacturing lines using automated systems, where batch traceability and impurity control are audited per global standards.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP <1079.1> Peptides and Oligonucleotides Quality Attribute Testing
• European Pharmacopoeia 10.0, Section 2.9.40 for Peptides Analysis
• GMP API raw material supplier qualification audits

Typical usage ratio

• 0.5–10 mol% of the total amino acid units in solid-phase peptide reactions; ratio depends on the length and target site of iodinated residues within specific peptides. Adjusted according to the required incorporation pattern and API specification.

Downstream process integration

• Loaded onto resin at the initial coupling stage or introduced at predefined sequence positions during chain elongation. Removal of the Boc group occurs post-synthesis before deprotection and cleavage.

Final product types

• Thyrotropin receptor-binding peptides (e.g., for thyroid cancer diagnostics)
• Radiolabeled (I-125, I-131) peptides for imaging and therapy
• Iodinated peptide drugs for metabolic disorder R&D
• Reference standards in GMP analytical labs

2. API Intermediate Manufacturing (Thyroid Hormone Synthesis)

This compound functions as a key protected precursor for multiple thyronine and thyroxine derivatives, notably in the staged synthesis of levothyroxine (T4) and liothyronine (T3) APIs. Strict control over stoichiometry and reaction contaminants is mandatory in these steps due to their downstream conversion into registered pharmaceuticals subject to regulatory filing. Boc-3,5-Diiodo-L-Tyrosine undergoes alkylation or oxidative coupling to introduce the iodoarene motif at defined positions, ensuring the correct regioselectivity required for API identity. Our plant integrates tailored purification and in-process controls based on customer DMF and CEP requirements.

Industry compliance standards

• US FDA 21 CFR Part 211 Finished Pharmaceuticals
• ICH Q3A/B Impurity Guidelines
• EMA “Guideline on the Chemistry of Active Substances”
• EDQM CEP/ASMF technical file standards

Typical usage ratio

• 0.8–1.2 molar equivalents relative to condensation substrates in multi-step syntheses; adjusted for overall purity, recovered yield, and impurity profile in downstream steps.

Downstream process integration

• Employed during the early or mid-stage of thyronine core assembly, followed by sequential deprotection, halogen exchange, and product crystallization. Excess monitored via HPLC during scale-up runs.

Final product types

• Levothyroxine sodium (T4) API
• Liothyronine sodium (T3) API
• Tetraiodothyroacetic acid research standards
• Hydrochloride/acetate salt forms of thyroid hormone analogues

3. Radiopharmaceutical Precursor Supply

The diiodo structure of this intermediate provides stable anchoring points for radiolabel incorporation via electrophilic or oxidative iodine exchange, facilitating precise labeling with isotopes such as I-125 and I-131. Downstream, it forms the radiolabeled moiety in compounds for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Our controlled synthesis supports requirements for radiochemical purity and safe handling. Radiopharmaceutical manufacturers specify shipment terms and supply chain documentation to ensure compliance with hospital and clinical batch release criteria.

Industry compliance standards

• Good Radiopharmacy Practice (GRPP, European Association of Nuclear Medicine)
• US NRC regulations for handling radioactive compounds
• USP <825> Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging
• ISO 21474-2:2021 for Radiopharmaceutical Synthesis

Typical usage ratio

• Used equimolar with radioactive iodide source; typical process loads are 0.1–1 mmol per batch, scaled by tracer activity and formulation requirements.

Downstream process integration

• Dissolved and introduced prior to iodine isotope exchange; post-radiolabeling, product is purified (e.g., by HPLC) and compounded for injection or diagnostic use.

Final product types

• I-125 radiolabeled peptides for thyroid imaging
• I-131 radiotherapeutics for thyroid ablation
• Radioactive reference markers for laboratory calibration
• Precursor kits for hospital nuclear medicine departments

4. Fine Chemical R&D and High-Purity Analytical Standard Preparation

Boc-3,5-Diiodo-L-Tyrosine is an essential component in the preparation of custom analytical standards, utilized by pharmaceutical QC laboratories and contract development companies engaged in method validation and impurity profiling. The protected structure allows for sequential deprotection, derivatization, or coupling to tags used in high-resolution mass spectrometry or HPLC calibration. Downstream labs utilize precisely weighed aliquots to establish analytical response factors and for tracing reaction by-products in research or process validation studies. Manufacturing lots undergo extensive QC batch release with certification of chromatographic and spectroscopic identity as required by customer protocols.

Industry compliance standards

• ISO/IEC 17025 Laboratory Accreditation
• ICH Q2(R1) Validation of Analytical Procedures
• USP/NF Reference Standard Certification
• EU GMP Part II for quality-related reference materials

Typical usage ratio

• Prepared in stock solutions at 0.01–10 mg/mL based on intended calibration range; actual working dilution established according to detection limits and method design.

Downstream process integration

• Direct weighing, followed by dissolution into analytical-grade solvents; often derivatized post-deprotection for assay method development and system suitability tests.

Final product types

• Certified analytical standards for pharmaceutical QC
• Method development kits for LC-MS validation
• Isotopic internal standards for trace impurity analysis
• Specialty labeling reagents for biochemical research